# Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

> **NCT01724580** · — · APPROVED_FOR_MARKETING · sponsor: **Eli Lilly and Company**

## Conditions studied

- Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
- Juvenile Dermatomyositis (JDM)
- Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
- Aicardi-Goutières Syndrome (AGS)

## Interventions

- **DRUG:** Baricitinib

## Key facts

- **NCT ID:** NCT01724580
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724580, "Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01724580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*